2008-07-02 19:47:18 -
www.companiesandmarkets.com adds new report - Warner Chilcott Ltd - Premium Company Profile www.companiesandmarkets.com/Summary-Company-Profile/Warner-Chilc ..
Introduction
Warner Chilcott is a specialty pharmaceutical company focused on two therapeutic segments: women´s health and dermatology. The company´s predecessor company was purchased by a private equity consortium in January 2005. The company has a strong portfolio of marketed and pipeline products.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial
trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Warner Chilcott is engaged in developing, manufacturing ,marketing and selling branded prescription products in women´s healthcare and dermatology. Women´s healthcare related products include Loestrin 24 FE, Ovcon 35 and Ovcon 50, Femcon FE, Estrostep FE, Femhrt and Estrace Cream and Dermatology related products include Taclonex, Dovonex and Doryx.
The company´s total revenues increased at a CAGR of 34% during 2002-2006, from $235 million to $754 million. The company´s biggest contributor to revenue growth during 2002-2006 was product sales which recorded revenues of $752 million for the fiscal year 2006. The major contributors were Dovonex, Estrostep FE, Taclonex,Femhrt, and Loestrin 24 FE.
The company´s biggest contributor to sales growth out to 2010 will be the sales of Loestrin 24 FE, indicated for the prevention of pregnancy in women. Revenues from Loestrin are expected to increase at a CAGR of 59%, from $44 million in 2006 to $284 million in 2010. This represents an absolute growth of +$240 million
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
